Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07 · 8-K

Esperion Therapeutics, Inc.

Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. At a special meeting of stockholders of Esperion Therapeutics, Inc. (the “Company”) held on July 8, 2026 (the “Special Meeting”), the Company’s stockholders voted to adopt the Agreement and Plan of Merger, dated as of May 1, 2026 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Essence Parent…

Filed Jul 8, 2026Accepted Jul 8, 2026, 8:32 AM EDTCIK 1434868Accession 0001104659-26-081588
Share

Company context

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Esperion Therapeutics, Inc.Jul 31, 2026
  2. 15-12G filingJul 23, 2026
  3. EFFECT filingJul 15, 2026
  4. EFFECT filingJul 15, 2026
  5. EFFECT filingJul 15, 2026

Registered securities in this filing

Esperion Therapeutics, Inc. · 8-K · Filed 2026-07-08

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.001 per share

Symbol
ESPR
Exchange
NASDAQ
Classification
COMMON
Status
Historical · closed Jul 13, 2026
Filing context

Context: AsOf2026-07-08

Dimensions: Not supplied

Accession 000110465926081588 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders. At a special meeting of stockholders of Esperion Therapeutics, Inc. (the “Company”) held on July 8, 2026 (the “Special Meeting”), the Company’s stockholders voted to adopt the Agreement and Plan of Merger, dated as of May 1, 2026 (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, Essence Parent Inc., a Delaware corporation (“Parent”), and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (“MergerCo”) and to approve the transactions contemplated by the Merger Agreement, including the merger, but excluding the debt-financing and any Parent co-investment. Pursuant to the Merger Agreement, and subject to the conditions set forth therein, MergerCo will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger Agreement Proposal”). As of the close of business on May 28, 2026, the record date for the Special Meeting, there were 257,693,347 issued and outstanding shares of the Company’s common stock, par value $0.001 per share (“Company Stock”), entitled to vote at the Special Meeting. At the Special Meeting, the holders of a total of 158,573,615 shares of Company Stock, representing 61.53% of the issued and outstanding shares of Company Stock entitled to vote at the Special Meeting, were represented virtually or by proxy, constituting a quorum. At the Special Meeting, the Company’s stockholders also considered a proposal to approve, by advisory (non-binding) vote, the compensation that may be paid or become payable to the Company’s named executive officers in connection with the consummation of the merger (the “Advisory Compensation Proposal”). The proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to at the time of the Special Meeting, was not voted on at the Special Meeting because there were sufficient votes to then approve the Merger Agreement Proposal. The results with respect to each proposal voted on at the Special Meeting are set forth below. The Merger Agreement Proposal The following votes were cast at the Special Meeting (virtually or by proxy), and based on the results from the Inspector of Election, the Merger Agreement Proposal was approved by the requisite vote of the Company’s stockholders: Votes For Votes Abstentions Broker Against Non-Votes ─────────────────────────────────────────────────────────────── 135,326,793 22,750,628 496,194 0 The Advisory Compensation Proposal The following votes were cast at the Special Meeting (virtually or by proxy), and based on the results from the Inspector of Election, the Advisory Compensation Proposal was approved by the requisite vote of the Company's stockholders: Votes For Votes Abstentions Broker Against Non-Votes ─────────────────────────────────────────────────────────────── 129,937,383 22,283,787 6,352,445 0

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.